Compounds > 4-hydroxy-2-(di-n-propylamino)indan

Page last updated: 2024-12-08

4-hydroxy-2-(di-n-propylamino)indan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxy-2-(di-n-propylamino)indan: RN & structure given in first source; RN refers to (R)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	146855
CHEMBL ID	85362
SCHEMBL ID	7445447
MeSH ID	M0130851

Synonyms (13)

Synonym
CHEMBL85362 ,
4-hdpi
bdbm50107867
2-dipropylamino-indan-4-ol
(r)-2-dipropylamino-indan-4-ol
(s)-2-dipropylamino-indan-4-ol
1h-inden-4-ol, 2-(dipropylamino)-2,3-dihydro-, (r)-
94843-89-7
4-hydroxy-2-(di-n-propylamino)indan
SCHEMBL7445447
2-(dipropylamino)-2,3-dihydro-1h-inden-4-olato(2-)
DTXSID40915280
4-hydroxy-2-(di-n-propyl-amino)indan

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
D(3) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.0420	0.0001	0.2567	5.8000	AID65611
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	Ki	0.0195	0.0001	0.7396	10.0000	AID4009
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)	Ki	0.0420	0.0003	0.3708	8.1600	AID65611
D(2) dopamine receptor	Rattus norvegicus (Norway rat)	Ki	0.0052	0.0000	0.4375	10.0000	AID65244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay ID	Title	Year	Journal	Article
AID62367	Total dose at which the animal vomits	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4	Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
AID62016	Potency was evaluated for the activity against Dopamine receptor D2 of cat cardioaccelerator nerve preparation; Active	1986	Journal of medicinal chemistry, Dec, Volume: 29, Issue:12	p-Dimethoxy-substituted trans-octahydrobenzo[f]- and -[g]quinolines: synthesis and assessment of dopaminergic agonist effects.
AID173610	Estimated dose giving an approximately maximal decrease of the DA synthesis rate	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4	Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
AID176388	Estimated dose giving a half-maximal decrease of the DA synthesis rate in the striatum of rat brain	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4	Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
AID65611	Affinity at rat D3 dopamine receptor on CHO cell membranes by [3H]spiperone displacement.	2001	Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26	Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID170426	Motor activity in reserpinized rats at the biochemical ED50 dose level expressed as accumulation counts per 60 min	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4	Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
AID176386	Estimated dose giving a half-maximal decrease of the DA synthesis rate in the limbic system of rat brain	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4	Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
AID170424	Motor activity in reserpinized rats at the biochemical ED100 dose level expressed as accumulation counts per 60 min	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4	Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
AID231639	Binding affinity ratio of D2/D3	2001	Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26	Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID4009	Binding affinity towards 5-hydroxytryptamine 1A receptor	2001	Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26	Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
AID195682	DA-agonist induced motor activity in reserpinized rat was measured; 0.5-1.2	1981	Journal of medicinal chemistry, Apr, Volume: 24, Issue:4	Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity.
AID65244	Affinity at D2 dopamine receptor on CHO cell membranes by [3H]PNU-86170 displacement.	2001	Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26	Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (80.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.34 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.14 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	1.96	1	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
u 99194 [no description available]	2	1	0	indanes
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.37	2	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
u 93385 U 93385: cis-isomer more active than trans-isomer; has good oral availability; structure given in first source	2	1	0
5-hydroxy-2-n,n-dipropylaminotetralin 5-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation	2.37	2	0